News Category
In vitro ADME studies provide critical early insights into drug candidates' behavior, reducing costly late-stage failures and accelerating development...
GeoVax's enhanced MVA vaccine, MVA-X, provides durable single-dose protection against lethal Clade I mpox and other orthopoxviruses in preclinical mod...
Onco-Innovations is advancing its preclinical cancer candidate ONC010 toward first-in-human testing by aligning manufacturing, formulation, and regula...
VERAXA Biotech has named Raju Willener as CFO, bringing over 30 years of capital markets experience to support the advancement of its BiTAC oncology p...
Apimeds Pharmaceuticals US, Inc. has hired IBN to enhance corporate communications, aiming to raise investor awareness for its digital asset infrastru...
Regentis Biomaterials' CEO discussed the European commercialization and U.S. pivotal study of GelrinC, a potential off-the-shelf treatment for knee ca...
Silo Pharma's U.S. patent allowance for SPC-15 strengthens its intellectual property position in developing a novel intranasal treatment for PTSD, a c...
Regentis Biomaterials has moved its off-the-shelf hydrogel implant GelrinC into a pivotal FDA-authorized study, potentially addressing a 470,000-case ...
Accelerated biological aging is emerging as a key explanation for the increasing incidence of cancer in adults under 55, with implications for prevent...
VERAXA Biotech's appointment of Raju Willener as CFO brings over 30 years of capital markets expertise to advance its BiTAC oncology pipeline and pote...
Regentis Biomaterials' GelrinC hydrogel implant aims to regenerate knee cartilage, offering a potential alternative to symptom management and addressi...
Med-X Inc. is accelerating the growth of its Nature-Cide natural pest-control brand as it prepares for a Nasdaq debut, with recent OMRI certification ...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition across human and canine osteosarcoma cell lines, suggesting a potential dual-purpos...
Quantum BioPharma's FDA clearance of its IND for Lucid-MS enables a Phase 2 trial in multiple sclerosis, potentially advancing a novel treatment that ...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for independent testing of GEO-MVA could accelerate the vaccine's development a...
Creative Biolabs has expanded its functionalized lipid-based delivery system development to help researchers address stability, targeting, and control...
Creative Biolabs has upgraded its single-cell multi-omics and RNA sequencing services, offering end-to-end solutions that enable high-resolution cellu...
A comprehensive review reveals that the tumor microenvironment actively reshapes natural killer cells into distinct functional subsets, offering new t...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its mpox vaccine and cancer immunotherapy programs.
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Regentis Biomaterials reported first-half 2026 results, highlighting progress in its Phase III GelrinC trial, expanded clinical networks, and a new ma...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting drug, receives FDA clearance for a Phase 2 trial in multiple sclerosis, potentially o...
TransCode Therapeutics names John Tattory as interim CFO after Tom Fitzgerald's retirement, bringing extensive financial leadership to support the com...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager and broa...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is advancing to a Phase 2 trial for multiple sclerosis after FDA clearance...
Quantum BioPharma receives FDA clearance for the first-ever phase 2 trial of a myelin-rebuilding drug for multiple sclerosis, a potential game-changer...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and rebuild myelin, marks a historic d...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, providing a platform to highlight the compa...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets PNKP and uses two selectivity mechanisms, and its potential to...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, positions the company to potenti...
American Fusion Inc. has moved its Texatron fusion program into a more demanding test phase, achieving record pressures and attracting new research co...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing therapies to overcome cancer drug...
Nutriband's CEO participation in the Nasdaq LaB Biotech Summit underscores the company's strategic positioning in the biotech sector and its focus on ...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its commitment to advancing SPC-15, a nose-to-brain PTSD treatment,...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a significant milestone for a novel myelin-repair approach in multiple sclerosis, p...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective drug candidate, has received FDA clearance to begin a Phase 2 clinical trial, a miles...
Helus Pharma's CEO participation in a major investment conference underscores the company's clinical advancements and strategic positioning in the men...
GeoVax supports the new global mpox vaccine stockpile, emphasizing its GEO-MVA candidate's readiness to bolster diversified vaccine supply and global ...
Voyageur Pharmaceuticals receives a $1 million payment from Bayer after achieving the first milestone in their collaboration, advancing toward domesti...
Greenland Mines announces Q4 biotech spin-off and key milestones, including Nasdaq compliance and Sarfartoq acquisition, positioning itself as a major...
VERAXA Biotech's appointment of Raju Willener as CFO brings seasoned financial leadership to guide the company's capital strategy and advancement of i...
Scinai Immunotherapeutics strategically shifts its R&D focus to its NanoAb platform and CDMO business after the expiration of its license with PinCell...
Onco-Innovations advances its oncology pipeline by completing manufacturing milestones, IND-enabling activities, and securing funding, positioning its...
OS Animal Health's participation in the Moody Capital conference highlights its strategic push to advance OST-HER2 for canine osteosarcoma and secure ...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class myelin repair candidate, marks a potential breakthrough in treating the underlyin...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class remyelinating agent, could address the unmet need for repairing my...
NanoViricides has registered its Phase II clinical trial for NV-387 Oral Gummies against Ebola viruses in the Pan African Clinical Trials Registry, ma...
Greenland Mines announces a Q4 2026 biotech spin-off and completes key acquisitions, positioning itself as a focused rare earths and critical minerals...
